Gilead Sciences (GILD) Receivables (2009 - 2026)
Gilead Sciences' (GILD) quarterly Receivables came in at $4.7 billion in Q1 2026, down 9.78% YoY from $5.3 billion in Q1 2025, and down 3.5% on a QoQ basis from $4.9 billion in Q4 2025.
Gilead Sciences (GILD) Receivables (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Receivables data on file, last reported at $4.7 billion in Q1 2026.
- Quarterly Receivables fell 9.78% year-over-year to $4.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 billion (down 9.78% YoY) and the FY2025 annual result came in at $5.9 billion, up 10.83% from the prior year.
- Receivables eased to $4.7 billion in Q1 2026, from $4.9 billion in the prior quarter.
- In the past five years, Receivables ranged from a high of $5.6 billion in Q2 2025 to a low of $3.8 billion in Q1 2022.
- A 5-year average of $4.8 billion and a median of $4.8 billion in 2022 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables fell 18.66% — and 2024, when it jumped 32.58%.
- Tracing GILD's Receivables over 5 years: stood at $4.8 billion in 2022, then fell by 2.45% to $4.7 billion in 2023, then dropped by 5.15% to $4.4 billion in 2024, then advanced by 11.15% to $4.9 billion in 2025, then retreated by 3.5% to $4.7 billion in 2026.
- The last three Receivables figures came in at $4.7 billion (Q1 2026), $4.9 billion (Q4 2025), and $5.1 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 10.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.90 Bn |
| Mar 31, 2026 | 4.74 Bn |
| Dec 31, 2025 | 4.91 Bn |
| Sep 30, 2025 | 5.10 Bn |
| Jun 30, 2025 | 5.62 Bn |
| Mar 31, 2025 | 5.26 Bn |
| Dec 31, 2024 | 4.42 Bn |
| Sep 30, 2024 | 4.59 Bn |
| Jun 30, 2024 | 5.49 Bn |
| Mar 31, 2024 | 5.52 Bn |
| Dec 31, 2023 | 4.66 Bn |
| Sep 30, 2023 | 5.59 Bn |
| Jun 30, 2023 | 5.05 Bn |
| Mar 31, 2023 | 4.16 Bn |
| Dec 31, 2022 | 4.78 Bn |
| Sep 30, 2022 | 4.35 Bn |
| Jun 30, 2022 | 4.12 Bn |
| Mar 31, 2022 | 3.79 Bn |
| Dec 31, 2021 | 4.49 Bn |
| Sep 30, 2021 | 4.57 Bn |